Although there is a clear increase in bacteria “resistant” to standard therapies in a “test tube”, the real importance of resistance is when it becomes a clinical problem because of decreased effectiveness to treat serious life-threatening disease in patients by affecting clinical outcomes, such as mortality, decreased function and decreased quality of life for patients. For some diseases that are self-resolving and for which antibiotics aren’t required (e.g., sinusitis, bronchitis, otitis media, skin abscesses), identification of antibiotic resistance remains a test tube phenomenon with little impact on patient outcomes. More concerning illnesses, such as serious disease due to methicillin-resistant S. aureus (MRSA), resistance may indeed result in decreased effectiveness for some older drugs but many therapies still remain and many new therapies currently exist to treat MRSA. Arrevus is focusing its drug development efforts on those diseases for which antibiotic resistance has important clinical implications and for which few therapies exist. These efforts are dedicated to the development of Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (“DPCs”).